{"id":"clopidogrel-and-proton-pump-inhibitors","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Dyspepsia (when combined with PPI)"},{"rate":null,"effect":"Thrombotic events (due to reduced clopidogrel efficacy)"}]},"_chembl":{"chemblId":"CHEMBL1771","moleculeType":"Small molecule","molecularWeight":"321.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clopidogrel is a prodrug that requires hepatic metabolism via CYP3A4 and CYP2C19 to become active. Proton pump inhibitors (PPIs) are potent CYP2C19 inhibitors that significantly reduce clopidogrel's conversion to its active metabolite, thereby diminishing its antiplatelet effect. This drug-drug interaction is a recognized clinical concern that may increase thrombotic risk in patients requiring dual antiplatelet therapy.","oneSentence":"Clopidogrel is a P2Y12 inhibitor that reduces platelet aggregation, but proton pump inhibitors impair its activation, reducing its antiplatelet efficacy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:30:18.851Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Percutaneous coronary intervention with stent placement"},{"name":"Stroke prevention in patients with recent myocardial infarction or stroke"}]},"trialDetails":[{"nctId":"NCT03764241","phase":"PHASE3","title":"Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-02-01","conditions":"ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus","enrollment":280},{"nctId":"NCT05574374","phase":"PHASE1","title":"Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-09-21","conditions":"Drug Drug Interaction","enrollment":36},{"nctId":"NCT03786757","phase":"PHASE3","title":"Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2019-04-01","conditions":"ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus","enrollment":200},{"nctId":"NCT01433978","phase":"PHASE3","title":"A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2012-03-26","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":24},{"nctId":"NCT01438840","phase":"PHASE3","title":"Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-02-16","conditions":"Chronic Thrombocytopenia, Immune Thrombocytopenia","enrollment":49},{"nctId":"NCT01138969","phase":"PHASE2","title":"Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2008-08","conditions":"Peptic Ulcer","enrollment":165},{"nctId":"NCT01231867","phase":"","title":"Cohort Study of Clopidogrel and Proton Pump Inhibitors","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2010-12","conditions":"Coronary Heart Disease, Acute Coronary Syndrome, Drug Interactions","enrollment":24471},{"nctId":"NCT01018940","phase":"","title":"Influence of the Proton Pump Inhibitor Omeprazole on the Anti-Platelet of P2Y12 Antagonists in Subjects With Coronary and Peripheral Artery Disease","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2010-01","conditions":"Coronary Artery Disease, Peripheral Artery Disease","enrollment":30},{"nctId":"NCT01621451","phase":"PHASE4","title":"Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD?","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2012-06","conditions":"Early Gastric Cancer, Gastric Dysplasia","enrollment":400},{"nctId":"NCT01175200","phase":"NA","title":"Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.","status":"COMPLETED","sponsor":"Ascopharm Groupe Novasco","startDate":"2010-09","conditions":"Anti Platelet Effects","enrollment":82},{"nctId":"NCT01170533","phase":"PHASE1","title":"PPI and Clopidogrel Response","status":"COMPLETED","sponsor":"University of Florida","startDate":"2009-03","conditions":"Drug Interaction","enrollment":20},{"nctId":"NCT00930670","phase":"PHASE4","title":"Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects","status":"COMPLETED","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2009-06","conditions":"Coronary Artery Disease","enrollment":320},{"nctId":"NCT00854776","phase":"NA","title":"Peptic Ulcer Disease in Ischemic Heart Patients Taking Aspirin and Clopidogrel With or Without Proton Pump Inhibitor","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2009-01","conditions":"Peptic Ulcer, Ulcer Complications","enrollment":300},{"nctId":"NCT01037491","phase":"NA","title":"Comparison of Ulcer Healing in Patients Taking Rabeprazole With Different Antiplatelets","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2009-10","conditions":"Gastric Ulcer, Duodenal Ulcer","enrollment":200},{"nctId":"NCT01023360","phase":"PHASE4","title":"Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping ™ Assay","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2008-05","conditions":"30 Healthy People","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["clopidogrel","rabeprazole","pantoprazole","esomeprazole"],"phase":"marketed","status":"active","brandName":"Clopidogrel and proton pump inhibitors","genericName":"Clopidogrel and proton pump inhibitors","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clopidogrel is a P2Y12 inhibitor that reduces platelet aggregation, but proton pump inhibitors impair its activation, reducing its antiplatelet efficacy. Used for Acute coronary syndrome, Percutaneous coronary intervention with stent placement, Stroke prevention in patients with recent myocardial infarction or stroke.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}